Supernus Pharmaceuticals, Inc.SUPNNASDAQ
Loading
Cash Flow Under PressureContracting
Percentile Rank36
3Y CAGR-26.6%
5Y CAGR-19.4%
Year-over-Year Change
Operating cash flow minus capital expenditures
3Y CAGR
-26.6%/yr
vs -2.4%/yr prior
5Y CAGR
-19.4%/yr
Recent deceleration
Acceleration
-24.3pp
Decelerating
Percentile
P36
Within normal range
vs 5Y Ago
0.3x
Contraction
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $45.99M | -73.1% |
| 2024 | $171.23M | +54.9% |
| 2023 | $110.53M | -5.1% |
| 2022 | $116.41M | -6.9% |
| 2021 | $125.08M | -7.3% |
| 2020 | $134.95M | -3.9% |
| 2019 | $140.39M | +9.6% |
| 2018 | $128.14M | +13.8% |
| 2017 | $112.61M | +72.7% |
| 2016 | $65.21M | - |